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Abstract
Backgroud: As magicians of the DNA world, topoisomerases resolve all of the topological problems in relation to
DNA during a variety of genetic processes. While the prognostic value of topoisomerase isoenzymes in epithelial
ovarian carcinoma (EOC) is still elusive. In current study, we investigated the prognostic value of topoisomerase
isoenzymes in the EOC patients. Kaplan Meier plotter (KM plotter) database were used to assess the relevance
of individual topoisomerase isoenzyme mRNA expression to EOC patients overall survival (OS), in which updated
survival information and gene expression data were from a total of 1,648 EOC patients.
Results: High expression of TOP1 and TOP2A were found to be correlated to worse OS in all patients and serous
patients, but not in endometrioid patients. Contrary to TOP1 and TOP2A, TOP3A and TOP3B expression were associated
with better OS in all patients and serous patients, but not in endometrioid patients. While TOP2B were not found any
significant prognostic value for EOC patients. From the Oncomine database, we also found widespread upregulation in
the expression of TOP1 and TOP2A genes in primary tumor tissues. Albeit limited in number, all datasets exhibiting
differential expression showed TOP3A and TOP3B under-regulated.
Conclusion: These results strongly supported that TOP1 and TOP2A were potential biomarkers for predicting poor
survival of EOC patients, while TOP3A and TOP3B were expected to be further exploited as tumor suppressors.
Comprehensive understanding of the topoisomerase isoforms may have guiding significance for the diagnosis
treatment and prognosis in EOC patients.
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Backgroud
Epithelial ovarian carcinoma (EOC) is one of the most
lethal gynecological malignancies and is usually diag-
nosed at an advanced stage with a low 5-year survival
rate of 25–30 %. Surgery for staging and optimal cytore-
duction followed by adjuvant chemotherapy with plat-
inum/paclitaxel combination is the standard treatment
guideline, which gets an achievement of high response
rate [1]. Although patients with EOC generally respond
to initial platinum-based chemotherapy, almost 70 % of
advanced stage patients will develop recurrent cancer,
[2] which is determined by the extent of residual tumor
at primary surgery and sensitivity to platinum-based
therapy Hence, there is a need to take into account the
use of second-line chemotherapeutic options for EOC
patients, such as retreatment with paclitaxel and carbo-
platin, as well as treatment with pegylated liposomal
doxorubicin (PLD), docetaxel, or gemcitabine, topote-
can, and avastin, with a response rate between 10 %
and 30 % [3, 4].
DNA topoisomerases have been described as the
targets of important anticancer agents, such as TOP1
targeted drugs-topotecan and irinotecan, TOP2 targeted
drugs-etoposide and doxorubicin etc. [5, 6] In addition,
alterations of topoisomerase enzymatic activity can also
lead to atypical multidrug resistance [7, 8].
The critical actions of DNA topoisomerases include
DNA strand separation for transcription and replication,
the flawless segregation of two identical copies of entire
genomes following replication, and the formidable
genomic compaction in cells. DNA topoisomerases are
classified as type I and type II, and the two types can be
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further divided into four subfamilies: IA, IB, IIA and IIB
[9, 10]. The human genome encodes six topoisomerases,
which include type IA, IB and IIA [11, 12]. Each of the
subfamilies IA (TOP3A and TOP3B), IB (TOP1 and
mitochondrial TOP1) and IIA (TOP2A and TOP2B), are
known for two enzymes [13, 14].
For type I enzymes, they transiently break the single
DNA strand at a time; on the contrary, for type II enzymes,
as a dimeric enzyme molecule, they transiently break a pair
of strands in a DNA double helix in concert. In contrast to
the type IA and IB DNA topoisomerases, the type IIA and
IIB enzymes catalyze the ATP dependent traverse of one in-
tact DNA duplex through another [15, 16].
Type IA (TOP3A and TOP3B) enzymes are the only
enzymes that relax negative but not positive supercoil-
ing. It resolves recombination intermediates and plays a
role as decatenase on nicked DNA during their replica-
tion. There is strong evidence that they physically inter-
acts with SGS1 helicase, [17, 18] as well as other
members of the RecQ family, [19, 20] indicating a func-
tion in maintaining genomic stability.
Type IB (TOP1) and type IIA (TOP2A and TOP2B)
enzymes mainly function to relax DNA to remove nega-
tive and positive supercoils during replication and tran-
scription. In eukaryotes, coiling a DNA into a compact
form can be implemented by either a type IB or a type II
enzyme [10]. TOP2A is tightly linked to cell multiplica-
tion, that is, its expression increases 2 to 3 fold during
G2/M and is orders of magnitude higher in rapidly pro-
liferating than in non-dividing cells. Whereas TOP2B is
also expressed in quiescent cells [5].
In EOC, TOP1 and TOP2A expression was observed
in a large proportion of cases (30–70 %) [21]. While,
there is limited data about the prognostic value of topo-
isomerase expression in ovarian cancer, especially of the
TOP3A and TOP3B. And a significant correlation be-
tween elevated topoisomerase expression and EOC sen-
sitivity to multidrug is still controversial. In this study,
we aimed at identifying the role of DNA topoisomerase
isoforms expression in the prognosis of EOC, which may
help to assess the patients’ risk profile and facilite the
development of more effective therapeutic strategies for
EOC patients.
Methods
The Kaplan Meier plotter
The Kaplan Meier plotter (KM plotter) was capable to as-
sess the effect of 54,675/22,277 genes on survival using
10,188 tumor samples, which included 1648 ovarian, 4142
breast, 1065 gastric and 2437 lung cancer patients with a
mean follow-up of 69/40/49/33 months (http://kmplot.-
com/analysis/). The background database was established
by the use of gene expression and patients survival infor-
mation from the Gene Expression Omnibus (GEO, http://
www.ncbi.nlm.nih.gov/geo/), Cancer Biomedical Informat-
ics Grid (caBIG, http://ncip.nci.nih.gov), European gen-
ome phenome archive (EGA, https://www.ebi.ac.uk/ega/),
and the Cancer Genome Atlas (TCGA, http://cancergen-
ome.nih.gov), which was handled by a MySQL server and
integrates clinical data and gene expression information
simultaneously [22–24].
With the purpose to analyze a particular gene’s prog-
nostic value, the cohorts were divided into two groups
according to the median (or upper/lower quartile) ex-
pression of the gene. The overall survival (OS), relapse
free survival (RFS), etc. could be compared between the
two groups [25]. Briefly, the five genes (TOP1A, TOP2A,
TOP2B, TOP3A, and TOP3B) were entered into the data-
base (http://kmplot.com/analysis/) respectively to obtain
the Kaplan-Meier survival plots in which the number at
risk was indicated below the main plot. Log rank P value
and hazard ratio (and 95 % confidence intervals) were cal-
culated and displayed on the webpage.
Oncomine analysis
Oncomine was a cancer microarray database and web-
based data mining platform aimed at facilitating new dis-
covery from genome-wide expression analyses, in which
exploration for differential expression analyses comparing
most major types of cancer with respective normal tissues
as well as clinical-based and pathology-based analyses
were available [26].
The individual gene expression level of TOP1A, TOP2A,
TOP2B, TOP3A, and TOP3B was analyzed using Onco-
mine. We compared mRNA levels of cancer vs. normal
patient datasets. In order to reduce false discovery
rate, we selected 2.0 fold change, P value = 0.01, and
Top 10 % as threshold.
Results
Among all the six topoisomerase genes, mitochondrial
TOP I was not found in www.kmplot.com, maybe on
account of its peculiarity from the nuclear genome
and we concluded the other five topoisomerase genes
in this article.
First, we examined the prognostic value of the expres-
sion of TOP1 in www.kmplot.com. The desired Affyme-
trix was valid: 208900_s_at (TOP1). Survival curves were
plotted for all patients (n = 1,582), for serous (n = 1138),
and for the endometrioid (n = 36). It was found that
TOP1 mRNA high expression was correlated to signifi-
cantly worse OS for all EOC patients followed for
20 years, (HR 1.22 [1.07–1.39], P = 0.0035) (Fig. 1a). In
addition, TOP1 mRNA high expression was also found
to be correlated to significantly worse OS in serous pa-
tients, (HR 1.24 [1.05–1.46], P = 0.0091) (Fig. 1b), but in-
significantly better OS in endometrioid patients, (HR
0.28 [0.05–1.68], P = 0.14) (Fig. 1c).
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Then we determined the prognostic effect of the ex-
pression of TOP2A in www.kmplot.com. The desired
Affymetrix was valid: 201291_s_at (TOP2A). TOP2A
mRNA high expression was also found to be correlated to
significantly worse OS in all patients (n = 1582), (HR 1.26
[1.1–1.45], P = 0.00061) (Fig. 2a), and in serous patients
(n = 1138), (HR 1.32 [1.12–1.56], P = 0.001) (Fig. 2b), but
insignificantly better OS in endometrioid patients (n = 36),
(HR 0.31 [0.03–2.78], P = 0.27) (Fig. 2c).
Figure 3 showed the prognostic effect of the expres-
sion of TOP2B in www.kmplot.com. The desired Affy-
metrix IDs was valid: 211987_at (TOP2B). However, the
curves showed that TOP2B expression above or below the
median in all EOC patients did not separate them into sig-
nificantly different prognostic groups, (n = 1582), (HR 1.14
[0.99–1.31], P = 0.061) (Fig. 3a). In addition, the curves
also did not show any differences among the serous
patients, (n = 1138), (HR 1.12 [0.96–1.32], P = 0.15)
(Fig. 3b), while, for endometrioid patients, albeit sepa-
rated into different groups, not significantly (n = 36),
(HR 4.14 [0.46–37.04], P = 0.17) (Fig. 3c).
Interestingly, TOP3A and TOP3B expression showed
favorable prognostic value in www.kmplot.com. The de-
sired Affymetrix IDs was valid: 204946_s_at (TOP3A).
The high expression of TOP3A was found to be corre-
lated to significantly better OS for all EOC patients,
Fig. 1 The prognostic value of TOP1A expression. Notes: The desired Affymetrix ID is valid: 208900_s_at (TOP1A). a. Survival curves are plotted for
all patients (n = 1582). b. Survival curves are plotted for serous patients (n = 1138). c. Survival curves are plotted for endometrioid patients (n = 36).
Data was analyzed using Kaplan Meier Plotter (www.kmplot.com). Abbreviation: HR, hazard ratio; CI, confidence interval
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(n = 1582), (HR 0.83 [0.72–0.96], P = 0.011) (Fig. 4a),
and for serous patients, (n = 1138), (HR 0.83 [0.68–
0.99], P = 0.036) (Fig. 4b), but insignificantly worse OS
for endometrioid patients, (n = 36), (HR 381194811.58
[0 -lnf], P = 0.089) (Fig. 4c).
Next, the prognostic value of TOP3B in EOC pat-
ents was shown in Fig. 5. The desired Affymetrix IDs
was valid: 215781_s_at (TOP3B). The TOP3B high ex-
pression was associated with the significantly better OS in
all EOC patients, (n = 1582), (HR 0.81 [0.7–0.93], P =
0.0036) (Fig. 5a), and in serous patients, (n = 1138), (HR
0.81 [0.69–0.95], P = 0.0094) (Fig. 5b). While for endome-
trioid patients, it was related to insignificantly worse prog-
nosis, (n = 36), (HR 4.38 [0.73–26.27], P = 0.077) (Fig. 5c).
We also sought to explore the relationship between
topoisomerases expression and the clinicopathological
features for the EOC patients, such as grades, clinical
stages, and TP53 mutation. As was shown in Table 1,
both of the TOP1 and TOP2A were found to be associ-
ated with significantly worse OS in all grade III EOC pa-
tients, nevertheless, both of the TOP3A and TOP3B
were correlated to significantly better OS in all grade III
EOC patients. From Table 2, both TOP2A and TOP2B
were found to be correlated to significantly shorter OS
in all stage I EOC patients and TOP1 was found to be
associated with insignificantly worse OS, while the ex-
pression of TOP3A and TOP3B indicated significantly
better OS in all stage III EOC patients. In EOC patients,
Fig. 2 The prognostic value of TOP2A expression. Notes: The desired Affymetrix ID is valid: 201291_s_at (TOP2A). a. Survival curves are plotted for
all patients (n = 1582). b. Survival curves are plotted for serous patients (n = 1138). c. Survival curves are plotted for endometrioid patients (n = 36).
Data was analyzed using Kaplan Meier Plotter (www.kmplot.com). Abbreviation: HR, hazard ratio; CI, confidence interval
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negtive correlations between OS and TOP2A mRNA ex-
pression companied by TP53 mutation or TOP1 mRNA
expression with wild TP53were revealed. Although insig-
nificant OS for patients by other genes, individually they
showed opposite prognostic value between TP53 wild
type or mutation type patients, implying the correlation
between topo members and TP53 (Table 3).
Given that the expression level of the five genes had
significant influence on patients’ survival, then we were
interested in investigating their differential expression
between normal and cancer tissues. Therefore, we ex-
tracted the summary data on transcript expression for
the individual gene from the Oncomine database for
most major tumors, focusing on datasets of clinical spec-
imens of cancer vs. normal patients.
As was shown in Fig. 6, for TOP1 (23 vs. 1), TOP2A
(165 vs. 8) and TOP2B (17 vs. 6), overwhelming majority
of the datasets with differential expression showed gene
overexpression in tumor vs. normal tissues. For TOP3A
(0 vs. 6) and TOP3B (0 vs. 2), although limited, all data-
sets with any expression changes, showed gene downreg-
ulation in tumor vs. normal tissues. It was accordant to
the better OS for the TOP1, and TOP2A and worse OS
for the TOP3A and Top3B.
Discussion
By allowing DNA double helices or strands to pass
through each other, DNA topoisomerases could solve all
of the topological problems of deoxyribonucleic acid in
replication, transcription and other cellular transactions.
Fig. 3 The prognostic value of TOP2B expression. Notes: The desired Affymetrix ID is valid: 211987_at (TOP2B). a. Survival curves are plotted for all
patients (n = 1582). b. Survival curves are plotted for serous patients (n = 1138). c. Survival curves are plotted for endometrioid patients (n = 36).
Data was analyzed using Kaplan Meier Plotter (www.kmplot.com). Abbreviation: HR, hazard ratio; CI, confidence interval
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TOP1, TOP2A and TOP2B levels in several human can-
cers were reported to be higher than those of normal or
benign tissues, [7, 21, 27, 28] which was in accordance
to the results from Oncomine.
Numerous reports had demonstrated that the TOP1
gene copy number, mRNA and protein level, as well as
enzyme activity were associated with unfavorable prog-
nosis in oncotherapy [29–31]. Only individual data re-
vealed the prognostic effect of topoisomerase expression
in EOC patients, and our large-scale analysis that the
negative correlation between the TOP1 and prognosis
might have profound significance. Lee et.al revealed that
the overexpression of TOP1 in EOC was correlated to
the International Federation of Gynecologists and Ob-
stetricians (FIGO) stages and was associated with ad-
vanced stage [30], which might reflect a high progressive
growth of ovarian cancer. However, some other studies
found that no obvious correlation was observed between
the TOP1 expression and the staging and grading of
ovarian cancer [32, 33]. In our current study, the high
expression of TOP1 predicted insignificantly worse OS
in clinical stage I and II patients and significantly worse
OS in the pathological grade III patients.
Manipulating topoisomerase activity by poisoning or
catalytic inhibition has been widely mined to kill cancer
cells [5, 34, 35] Stabilization of topoisomerase cleavage
Fig. 4 The prognostic value of TOP3A expression. Notes: The desired Affymetrix ID is valid: 204946_s_at (TOP3A). a. Survival curves are plotted for
all patients (n = 1582). b. Survival curves are plotted forserous patients (n = 1138). c. Survival curves are plotted for endometrioid patients (n = 36).
Data was analyzed using Kaplan Meier Plotter (http://kmplot.com/analysis/). Abbreviation: HR, hazard ratio; CI, confidence interval
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complex (TOPcc) is one of the most reported and clinic-
ally important steps, of which by misaligning the DNA
ends, preventing re-ligation, and thus trapping the
enzyme on DNA, creating protein-linked DNA breaks
(PDBs), eventually damaging DNA, inducing cell cycle
arrest, even apoptotic cell death [36]. The enzymatic
activities of topoisomerases can be interfered at various
stages, such as binding to DNA or the combining and
hydrolysis of ATP [37].
Several studies had indicated that TOP1 overexpres-
sion in human solid tumors maybe a potential predictive
biomarker for TOP1 poisons [30, 32, 38, 39]. As topo-
isomerase I inhibitors, topotecan and irinotecan were
FDA approved drugs used for the second-line chemo-
therapy of advanced or recurrent ovarian cancer patients
due to refractory to first line drugs, e.g. paclitaxel plus
platinum-based doublet chemotherapy. In our results,
TOP1 expression above or below the median still signifi-
cantly separated all patients, with chemotherapy process
containing topoisomerase I inhibitor-topotecan, into
different prognostic groups (Additional file 1: Table S1).
The possible reasons might include: ① It was reported
that in colorectal cancer the TOP1 inhibitor could induce
autophagy and reduce apoptosis by activating the AMPK-
TSC2-mTOR pathway [40]; Besides, topotecan could
induce cytoprotective autophagy in wild-type TP53 colon
Fig. 5 The prognostic value of TOP3B expression. Notes: The desired Affymetrix ID is valid: 215781_s_at (TOP3B). a. Survival curves are plotted for
all patients (n = 1582). b. Survival curves are plotted for serous patients (n = 1138). c. Survival curves are plotted for endometrioid patients (n = 36).
Data was analyzed using Kaplan Meier Plotter (www.kmplot.com). Abbreviation: HR, hazard ratio; CI, confidence interval
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cancer cells while not in TP53 mutanted or knockout cells
[41]. ② Some mutations at G717V and T729I amino acid
residues of TOP1 gene were identified to exert a syner-
getic effect on CPT resistance by targeting the catalytic
site of the TOP1-DNA complexes [42]. ③ Zander et al.
had identified that overexpression of Abcg2/Bcrp and sig-
nificant reduced protein levels of the drug target TOP1
(without changing the levels of mRNA) maybe mecha-
nisms of in vivo resistance [43]. ④ In patients, the subse-
quent single-agent chemotherapy with non-platinum
Table 1 Correlation of topoisomerase isoenzymes with tumor grade of all EOC patients
Topoisomerases Grades Case-low Case-high HR (% 95 CI) P-value
TOP1 I 20 38 2.07 (0.59 − 7.28) 0.25
II 105 210 1.29 (0.9 − 1.85) 0.16
III 405 563 1.3 (1.09 − 1.55) 0.0033
TOP2A I 38 18 2.79 (1.04 − 7.47) 0.033
II 92 223 1.46 (1.07 − 1.98) 0.016
III 275 693 1.21 (1.02 − 1.44) 0.028
TOP2B I 34 22 0.51 (0.18 − 1.41) 0.18
II 200 115 1.48 (1.08 − 2.02) 0.014
III 249 719 1.12 (0.92 − 1.36) 0.27
TOP3A I 36 20 0.48 (0.17 − 1.37) 0.16
II 103 212 0.79 (0.58 − 1.09) 0.16
III 670 298 0.8 (0.66 − 0.97) 0.021
TOP3B I 41 15 0.48 (0.14 − 1.69) 0.25
II 137 178 1.25 (0.91 − 1.7) 0.16
III 698 270 0.73 (0.6 − 0.88) 0.0012
Abbreviation: HR hazard ratio; CI confidence interval
Table 2 Correlation of topoisomerase isoenzymes with clinical stage of all EOC patients
Topoisomerases Clinical stages Case-low Case-high HR (%95 CI) P-value
TOP1 I 19 55 4.47 (0.57 − 34.8) 0.12
II 43 16 2.54 (0.81 − 7.91) 0.096
III 718 264 1.18 (0.97 − 1.42) 0.096
IV 69 97 1.17 (0.8 − 1.71) 0.43
TOP2A I 37 37 10.37 (3.04−35.44) 5.8e − 06
II 25 34 2.04 (0.68 − 6.11) 0.19
III 277 705 1.21 (1−1.46) 0.053
IV 74 92 0.76 (0.52 − 1.13) 0.18
TOP2B I 34 40 4.64 (1.02 − 21.21) 0.029
II 24 35 0.29 (0.09 − 0.94) 0.028
III 249 719 0.87 (0.72 − 1.06) 0.18
IV 94 72 1.4 (0.96 − 2.06) 0.082
TOP3A I 54 20 1.84 (0.58 − 5.8) 0.29
II 42 17 0.44 (0.1 − 1.98) 0.27
III 716 266 0.7 (0.57 − 0.86) 0.00045
IV 59 107 0.74 (0.5 − 1.09) 0.13
TOP3B I 42 32 3.05 (0.91 − 10.2) 0.057
II 35 24 1.76 (0.58 − 5.33) 0.31
III 675 307 0.75 (0.63 − 0.91) 0.003
IV 64 102 0.73 (0.5 − 1.08) 0.11
Abbreviation: HR hazard ratio; CI confidence interval
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drugs would lead to a short-lived response rates of around
20 % [2].
Topoisomerase IIα (TOP2A) and topoisomerase IIβ
(TOP2B) were two different isoforms of type II topo-
isomerase, and they showed difference in biochemical,
pharmacological, and physiological properties. So far,
numerous studies had mainly focused on TOP2A. Ele-
vated TOP2A mRNA were observed in high grade ovar-
ian cancers as well as advanced stage diseases, and
patients with overexpression of nuclear TOP2A protein
had a marked decreased OS [44–46]. In our study, for
all EOC patients and serous patients, the TOP2A over-
expression was associated with significantly worse OS,
but insignificantly better OS in endomitrioid patients,
maybe due to tumor heterogeneity as well as the small
and unbalanced sample sizes. For patients with whether
low or high pathological grade, overexpression of
TOP2A indicated a shorter OS, but its high expression
in advanced stage patients is not associated with the sig-
nificantly better or worse OS.
The role of TOP2B in tumor was still controversial.
Being also expressed in quiescent cells in all tissues, the
expression level of TOP2B was not changed during the
cell cycle. [47] Few studies had focused on the correl-
ation between the overexpression of TOP2B and cancer
patients outcome. A study suggested that a type IIβ but
rather the type IIα topoisomerase was more closely cor-
related with the development of secondary malignancy,
treated by the type II topoisomerase targeting drugs,
such as doxorubicin and etoposide [48]. Song et al. re-
ported that the high expression level of the type IIβ
topoisomerase was correlated with longer survival in
acute myeloid leukaemia (AML) patients with M2 sub-
type [49]. Das et al. reported the increased exprtession
of TOP2B was associated with the sensitivity of neuro-
blastoma cells to etoposide [50]. Another study discov-
ered that the type IIβ protein levels correlated better
with type II topoisomerase activity than type IIα protein
levels and indicated type IIβ might be a target for
chemotherapy in ovarian cancer [51]. While in our
study, the high expression of TOP2B seemed irrelevant
to the prognosis of all EOC patients. The exact role of
TOP2B in tumor was expected to be elucidated.
The biologic role of TOP3 remained poorly under-
stood, as well as the prognosis value of TOP3A and
TOP3B in cancer patients. TOP3A was involved in DNA
repair surveillance and cell-cycle checkpoints aimed at
maintaining genomic stability possibly through format-
ting complex with BLM, RMI1, and RMI2 to form the
BLM complex to dissolution of double Holliday junc-
tions [52, 53]. It was reported that TOP3A interacted
with TP53, regulating the expression of TP53 and P21,
and contributed to the TP53-mediated tumor suppres-
sion [54]. TOP3B was the newest member of topoisom-
erase family, and played an important role in promoting
transcription, preventing DNA damage, and reducing
the frequency of chromosomal translocations [55]. It
was suggested that topoisomerase IIIβ played an essen-
tial role in chromosome stability in normal cells, as well
as in cancer cells [56]. Oliveira-Costa et al. [57] reported
that high expression of TOP3B was correlated to shorter
OS and metastasis in patients with invasive breast can-
cers. Different from above results, our results indicated
that both the overexpression of TOP3A and TOP3B
were associated with better OS in all EOC patients, as
well as serous patients, the idea of which was put for-
ward for the first time.
For the endometrioid patients, from Fig. 1 to Fig. 5,
the curves showed that the topoisomerase mRNA
above or below the median separated the cases into
significantly different prognostic groups, usually op-
posite to the all patients and serous patients. While,
maybe due to the small and unbalanced sample sizes,
five of the P values were greater than 0.05. If the
Table 3 Correlation of topoisomerase isoenzymes with TP53 status of all EOC patients
Topoisomerases TP53 status Case-low Case-high HR (% 95 CI) P-value
TOP1 Mutated 109 303 0.83 (0.63−1.09) 0.18
Wild type 54 32 1.91 (1.04−3.49) 0.033
TOP2A Mutated 278 161 1.32 (1.02−1.7) 0.036
Wild type 30 56 0.74 (0.41−1.33) 0.31
TOP2B Mutated 252 187 0.78 (0.6−1.02) 0.066
Wild type 38 48 1.34 (0.73−2.46) 0.34
TOP3A Mutated 300 139 1.17 (0.89−1.52) 0.26
Wild type 63 23 0.68 (0.33−1.42) 0.3
TOP3B Mutated 304 135 1.26 (0.97−1.64) 0.086
Wild type 42 44 1.45 (0.81−2.62) 0.21
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sample size was enlarged, the significant prognostic
value of topoisomerase isoforms mRNA in endome-
trioid patients might be seen. This reflected the het-
erogeneity between different subtypes of one tumor.
On account of their differential structures and functions,
the type IB (TOP1) or type II (TOP2A) enzymes are ex-
pected to be more suitable than type IA (TOP3A and
TOP3B) enzymes for solving the topological problems
that occurred during DNA chain elongation in replication
[10]. Based on previous evidences as well as our results,
TOP1 and TOP2A were strongly supported to potential
biomarkers for predicting poor survival of EOC patients,
while TOP3A and TOP3B were expected to be further
exploited for their potential antitumor effects.
Conclusion
Comprehensive understanding of the topoisomerase iso-
forms may have guiding significance for the diagnosis
and prognosis in EOC patients. On the basis of our
study, the discovery of the systematic molecular mecha-
nisms that how topoisomerase isoforms reflect or lead
Fig. 6 The individual gene expression level of TOP1A, TOP2A, TOP2B, TOP3A, and TOP3B in tumor vs. normal tissues. Notes: Various types of
cancer were shown in the figure. And the expression level of six topoisomerase family genes were shown in cancer vs normal tissue. Data was
analyzed using oncomine (www.oncomine.com). The datasets were obtained with the following parameters: P value threshold of 0.01, more than
2 fold change and top 10 % of the gene rank
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to different outcomes of tumor patients can pave a way
for more effective tumor diagnosis and treatment.
Additional file
Additional file 1: Table S1. Correlation of topoisomerase isoenzymes
with chemotherapy drugs contained in therapeutic regimen. (DOCX 16 kb)
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